Key Highlights

  • Quantum-Si (NASDAQ:QSI) traded at USD 1.22, up 14.02 percent in the screener snapshot on October 1, 2026, after rising 23 percent to about USD 0.98 on September 29.
  • Interim Proteus data showed 30 times more median alignments and a 4.8 times lower false discovery rate than the Platinum Pro instrument, using an 18 amino acid kit.
  • Cash and investments were USD 169.9 million at June 30, 2026, and the company says its runway extends into the fourth quarter of 2028.
  • Second-quarter Revenue was only USD 344 thousand, down 41.8 percent, and the net loss was USD 23.5 million, so the case rests on Proteus rather than current sales.

Data From the HUPO Congress

Quantum-Si (NASDAQ:QSI) released interim development results on September 28, 2026 and presented them at the World HUPO Congress in Singapore on September 29. Chief executive Jeff Hawkins called Proteus a fundamentally superior platform rather than a bigger Platinum Pro and said the system is not yet fully optimized. Volume reached 20.54 million shares on September 29 against a 100-day average of 2.85 million, so the move was heavily traded. The shares had closed at USD 0.795 on September 28.

How Single-Molecule Sequencing Works

The company reads proteins at the single-molecule level by attaching binders that recognize amino acids and recording their signals in thousands of tiny chambers. More chambers and cleaner signals produce more alignments, meaning peptide reads matched to a known protein. The interim data came from a control peptide study of four runs per platform and a 24-protein panel from a single chamber. Because the results are interim and company reported, independent validation and full-run performance remain unproven.

Risks and Timeline

The August 13, 2026 report delayed launch to the second quarter of 2027, announced a workforce reduction of about 20 percent and kept 2026 revenue guidance near USD 1.0 million with cash usage of USD 93.0 million or less. Customers are deferring Platinum purchases while they wait for Proteus, which explains the revenue decline of 41.8 percent in the second quarter. The stock closed below USD 1.00 as recently as September 28, a level that matters for Nasdaq listing rules, and the 200-day Moving Average near USD 1.01 is a resistance point in published technical data.

Where Things Stand

Quantum-Si (NASDAQ:QSI) rose because interim data gave investors the first quantitative evidence that Proteus can outperform Platinum Pro, not because current results improved. Revenue is minimal and losses are large, but cash of USD 169.9 million provides time. The next catalysts are further performance updates, the roadshow, and third-quarter results. Until Proteus ships in the second quarter of 2027, the stock remains a high-risk bet on execution.